Core Viewpoint - Koyuan Pharmaceutical has announced the termination of its plan to issue shares for asset acquisition and fundraising, citing changes in the overall market environment since the initial announcement of the transaction [1] Group 1: Termination of Asset Acquisition - Koyuan Pharmaceutical's board approved the termination of the share issuance for asset acquisition and related fundraising on November 28, 2025 [1] - The company intended to acquire 99.42% of Shandong Hongjitang Pharmaceutical Group Co., Ltd. from 38 trading parties, including Lino Investment Holding Group Co., Ltd. and Lino Group Co., Ltd. [1][2] - The decision to terminate the restructuring was made after careful consideration and discussions with relevant parties, aiming to protect the long-term interests of all shareholders [1] Group 2: Fundraising Details - Koyuan Pharmaceutical planned to raise up to 25 million yuan through the issuance of shares to no more than 35 qualified investors, which would not exceed 100% of the transaction price for the asset acquisition [2] - The total transaction price for the acquisition was set at 358,061.77 million yuan [2] - The independent financial advisor for this transaction was CITIC Securities [2] Group 3: Share Issuance and Financials - Koyuan Pharmaceutical's public offering raised a total of 854,883,000 yuan, with a net amount of 764,921,774.32 yuan after deducting issuance costs, which was 41,492.18 million yuan more than originally planned [4] - The funds raised were intended for projects including the technical transformation of raw material production lines and drug research and development [4] - The total issuance costs amounted to 89,961,225.68 yuan, with CITIC Securities receiving 73,939,470 yuan as underwriting and sponsorship fees [4]
科源制药终止收购宏济堂 去年10月份因消息刺激4涨停